Menu Search
Equities

Barinthus Biotherapeutics PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2AB:STU

Barinthus Biotherapeutics PLC

Actions
  • Price (EUR)0.590
  • Today's Change0.005 / 0.85%
  • Shares traded0.00
  • 1 Year change-36.22%
  • Beta-0.6489
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.

  • Revenue in USD (TTM)0.00
  • Net income in USD-75.88m
  • Incorporated2021
  • Employees105.00
  • Location
    Barinthus Biotherapeutics PLCThe Schrdinger BuildingHeatley Road, The Oxford Science ParkDIDCOT OX11 0DFUnited KingdomGBR
  • Phone+44 186 581 8808
  • Websitehttps://www.barinthusbio.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		2AB:FRA since
announced		Transaction
value
Clywedog Therapeutics IncAnnounced30 Sep 202530 Sep 2025Announced-39.39%--
Data delayed at least 15 minutes, as of Feb 06 2026 07:07 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.